Kite Pharma to Host Investor Day on October 18, 2016 Spotlighting an Industry-Leading CAR/TCR Pipeline, Next Generation Research and Development, and KTE-C19 Launch Readiness

SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will hold an
Investor Day on October 18, 2016 in New York where the company will
share updates on its advancing pipeline of chimeric antigen receptor
(CAR) and T cell receptor (TCR) product candidates, next generation
research and development programs, and KTE-C19 launch readiness. The
event and live webcast will begin at 12:00pm Eastern Time. The live
audio webcast can be accessed through the Events and Presentations
section under the Investors tab of Kite’s website at www.kitepharma.com.
Following the live audio webcast, a replay will be available on Kite’s
website for approximately 30 days.

About KTE-C19

Kite Pharma’s lead product candidate, KTE-C19, is an investigational
therapy in which a patient’s T cells are engineered to express a CAR to
target the antigen CD19, a protein expressed on the cell surface of
B-cell lymphomas and leukemias, and redirect the T cells to kill cancer
cells. KTE-C19 has been granted Breakthrough Therapy Designation status
for diffuse large B-cell lymphoma (DLBCL), transformed follicular
lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by
the U.S. Food and Drug Administration and Priority Medicines (PRIME)
regulatory support for DLBCL in the EU.

About Kite Pharma

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged
in the development of novel cancer immunotherapy products, with a
primary focus on engineered autologous cell therapy (eACT™) designed to
restore the immune system’s ability to recognize and eradicate tumors.
Kite is based in Santa Monica, CA. For more information on Kite Pharma,
please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
« predicts, » « believes, » « potential, » « proposed, » « continue, »
« estimates, » « anticipates, » « expects, » « plans, » « intends, » « may, »
« could, » « might, » « will, » « should » or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability to
advance the product pipeline, commercially launch KTE-C19 and research
and develop additional product candidates. Various factors may cause
differences between Kite’s expectations and actual results as discussed
in greater detail in Kite’s filings with the Securities and Exchange
Commission, including without limitation in its Form 10-Q for the
quarter ended June 30, 2016. Any forward-looking statements that are
made in this press release speak only as of the date of this press
release. Kite assumes no obligation to update the forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161011005536/en/